Kidney damage in gout (clinical observation)
https://doi.org/10.24412/2790-1289-2023-2-25-31
Abstract
Gout is a disease characterized by hyperuricemia and the deposition of urate crystals in the body tissues in the form of sodium monourate or uric acid. The cause of the disease is the excessive formation of uric acid and a decrease in its excretion by the kidneys, which leads to an increase in its concentration in the blood. Clinically, gout is manifested by recurrent acute arthritis and the formation of gouty nodes - tophi. Along with arthritis, one of the main clinical manifestations of gout is kidney damage. More often the disease occurs in men, but recently the prevalence of the disease among women has increased, with age the prevalence of gout increases. Despite the elementary nature of the clinical manifestations of gout, its diagnosis is still very difficult. On a clinical example, we consider typical errors that occur in the diagnosis of this pathology.
Supporting agencies: Absent
About the Authors
V. Poliakova
«North-Western State Medical University named after I. I. Mechnikov»
Russian Federation
Russian Federation
Valentina Poliakova, Candidate of Medical Sciences, Associate Professor
St. Petersburg
N. Kunitskaya
«North-Western State Medical University named after I. I. Mechnikov»
Russian Federation
Russian Federation
Nataliya Kunitskaya, Doctor of Medical Sciences, Professor
St. Petersburg
N. Leonteva
«North-Western State Medical University named after I. I. Mechnikov»
Russian Federation
Russian Federation
Natalia Leonteva, MD, Professor
St. Petersburg
References
1. Shin D.H. To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease. Kidney Res Clin Pract 38: 257–259, 2019.
2. Robinson P.C., Dalbeth N. Febuxostat for the treatment of hyperuricaemia in gout. Expert Opin Pharmacother. 2018 Aug;19(11):1289-1299.
3. Tsai C.W., Lin S.Y., Kuo C.C., Huang C.C. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One 12: e0170393, 2017.
4. Turner J.E., Becker M., Mittrücker H.W., Panzer U. Tissue-resident lymphocytes in the kidney. J Am Soc Nephrol 29: 389 – 399, 2018.
5. Xiao J., Fu C., Zhang X., Zhu D., Chen W., Lu Y., Ye Z. Soluble monosodium urate, but not its crystal, induces toll like receptor 4-dependent immune activation in renal mesangial cells. Mol Immunol 66: 310 – 318, 2015.
6. Xu X., Hu J., Song N., Chen R., Zhang T., Ding X. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol 18: 27, 2017.
7. Oh T.R., Choi H.S., Kim C.S., Bae E.H., Ma S.K., Sung S.A., Kim Y.S., Oh K.H., Ahn C., Kim S.W. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep 9: 6681, 2019.
8. Ejaz A.A., Johnson R.J., Shimada M., et al. The role of uric acid in acute kidney injury. NEPHRON. 2019;142(4):275–283. doi: 10.1159/000499939.
9. Zhou F., Yu G., Wang G., et al. Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m<sup>2</sup> and negative proteinuria. Clinical and Experimental Nephrology. 2019;23(7):871–879. doi: 10.1007/s10157-019-01705-w.
10. Hasegawa J., Maejima I., Iwamoto R., Yoshimori T. Selective autophagy: Lysophagy. Methods. 2015; 75:128–132. doi: 10.1016/j.ymeth.2014.12.014
11. Fan S., Zhang P., Wang A. Y., et al. Hyperuricemia and its related histopathological features on renal bi- opsy. BMC Nephrology. 2019;20(1): p. 95. doi: 10.1186/s12882-019-1275-4.
12. Schlee S., Bollheimer L. C., Bertsch T., Sieber C.C., Harle P. Crystal arthritides-gout and calcium pyrophosphate arthritis. Zeitschrift Fur Gerontologie Und Geriatrie. 2018;51(5):579–584. doi: 10.1007/s00391-017-1198-2
13. Yang L., Chang B., Guo Y., Wu X., Liu L. The role of oxidative stress-mediated apoptosis in the pathogenesis of uric acid nephropathy. Renal Failure. 2019;41(1):616–622. doi: 10.1080/0886022X.2019.1633350
14. Yu M.A., Sanchez-Lozada L.G., Johnson R.J., Kang D.H. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. Journal of Hypertension. 2010;28(6):1234–1242.
15. Song X., Sun Z., Chen G., et al. Matrix stiffening induces endothelial dysfunction via the TRPV4/microRNA-6740/endothelin-1 mechanotransduction pathway. Acta Biomaterialia. 2019; 100:52–60. doi: 10.1016/j.actbio.2019.10.013
16. Johnson R. J., Nakagawa T., Jalal D., Sanchez-Lozada L. G., Kang D.-H., Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrology, dialysis, transplantation. 2013; 28(9):2221–2228. doi: 10.1093/ndt/gft029
17. Lisa K Stamp, Tony R Merriman, Jasvinder A Singh. Expert opinion on emerging urate-lowering therapies. Expert Opin Emerg Drugs. 2018.23(3):201-209.
18. Kimura K., Hosoya T., Uchida S., Inaba M., Makino H., Maruyama S., Ito S., Yamamoto T., Tomino Y., Ohno I., Shibagaki Y., Iimuro S., Imai N., Kuwabara M., Hayakawa H., Ohtsu H., Ohashi Y. FEATHER Study Investigators. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72: 798 – 810, 2018.
19. Kojima S., Matsui K., Hiramitsu S., Hisatome I., Waki M., Uchiyama K., Yokota N., Tokutake E., Wakasa Y., Jinnouchi H., Kakuda H., Hayashi T., Kawai N., Mor H., Sugawara M., Ohya Y., Kimura K., Saito Y., Ogawa H. Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study. Eur Heart J 40: 1778 – 1786, 2019.
20. Ma G., Wang G., Xiao D., Teng W., Hui X., Ma G. Meta-analysis on allopurinol preventive intervention on contrast-induced acute kidney injury with random controlled trials: PRISMA. Medicine (Baltimore) 98: e15962, 2019.
21. Pascart T., Richette P. Investigational drugs for hyper- uricemia, an update on recent developments. Expert Opin Investig Drugs. 2018 May;27(5):437-444.
Review
For citations:
Poliakova V., Kunitskaya N., Leonteva N. Kidney damage in gout (clinical observation). Actual Problems of Theoretical and Clinical Medicine. 2023;(2):25-31. (In Russ.) https://doi.org/10.24412/2790-1289-2023-2-25-31
Views:
275
